Combining Intranasal Esketamine and Electroconvulsive Therapy in Severe Treatment‑Resistant Depression: A Case Series.
Sergi López-rodríguez, Aida De Arriba-Arnau, José Manuel Menchón, Pino Alonso, Mikel Urretavizcaya
The Journal of ECT January 29, 2026 DOI: 10.1097/yct.0000000000001233 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Case series Case report Peer reviewed |
|---|---|
| Sample size | 4 |
| Population | Adults aged 50 to 72 with severe treatment-resistant depression |
| Interventions | Electroconvulsive therapy Intranasal esketamine |
| Dose | 28 to 84 mg |
| Duration | 24 weeks |
| Topics | Depression Esketamine |
| Keywords | Case series Combination therapy Electroconvulsive therapy Maintenance treatment |
| Citations | 1 |
| Key findings | Combined ECT and esketamine was associated with sustained symptom improvement and wider ECT spacing in four patients with treatment-resistant depression. |
Abstract
This case series describes the combined use of electroconvulsive therapy (ECT) and intranasal esketamine (ESK)-2 rapidly acting, evidence-based options for treatment-resistant depression (TRD). Each can leave residual symptoms or early relapse. Whether concurrent use confers more durable benefit remains unclear. We followed 4 adults (50 to 72 y) with severe TRD who had shown partial or waning benefit to ECT or ESK alone. During acute treatment, bilateral ECT (2 to 3 sessions/wk) was paired with ESK (28 to 84 mg, 1 to 2 doses/wk) on non-ECT days. Over 24 weeks, ECT was tapered individually to every 1 to 3 weeks while ESK continued weekly or fortnightly, with schedules adjusted to course and tolerability. MADRS, ECT cadence, and adverse events were documented every 4 weeks. Two response profiles emerged. In 2 patients, adding the complementary modality to partial monotherapy produced sustained improvement: ESK added to ongoing ECT reduced MADRS from 36→18 (-50%), and ECT during ongoing ESK reduced MADRS from 35→22 (-37%). In 2 maintenance-ECT responders, adding ESK produced improvements from 42→16 (-62%) and 36→6 (-83%), allowing ECT intervals to extend from weekly to every 14 to 21 days. Mean symptom reduction was 58%; no relapses occurred over 24 weeks. Adverse events were mild and transient-brief dissociation (3/4) and post-ictal confusion (2/4); no serious events occurred. In this naturalistic series, combined ECT+ESK was feasible and associated with sustained symptom improvement, wider ECT spacing, and potentially lower cognitive burden. Findings are hypothesis-generating, support prospective controlled trials to define sequencing, dosing, and safety.
Comparable studies
Other case reports and case series on esketamine for depression, most cited first.